MCID: MNT002
MIFTS: 58

Mental Depression

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Mental Depression

MalaCards integrated aliases for Mental Depression:

Name: Mental Depression 12 29 15 71
Depressive Disorder 71
Depression 43

Classifications:



External Ids:

Disease Ontology 12 DOID:1596
MeSH 43 D003863
NCIt 49 C2982
ICD10 32 F32.9
UMLS 71 C0011570 C0011581

Summaries for Mental Depression

MalaCards based summary : Mental Depression, also known as depressive disorder, is related to major depressive disorder and postpartum depression, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Mental Depression is DCTN1 (Dynactin Subunit 1), and among its related pathways/superpathways are cAMP signaling pathway and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Valsartan and Reboxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Mental Depression

Diseases related to Mental Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2265)
# Related Disease Score Top Affiliating Genes
1 major depressive disorder 35.0 SLC6A4 POMC OXT MAOA LIPA HTR2C
2 postpartum depression 34.7 SLC6A4 POMC OXT MAOA LIPA HTR1A
3 atypical depressive disorder 34.7 SLC6A4 SERPINA3 POMC MAOA HTR2A HTR1A
4 bipolar disorder 34.2 SLC6A4 PRODH MAOA HTR2C HTR2A HTR1A
5 neurotic disorder 33.9 SLC6A4 MAOA HTR2A HTR1A BDNF
6 schizoaffective disorder 33.3 SLC6A4 PRODH HTR2A HTR1A COMT BDNF
7 depression 33.3 SLC6A4 MAOA HTR2C HTR2A HTR1A CRH
8 melancholia 33.2 SLC6A4 POMC MAOA HTR2A HTR1A CRH
9 anxiety 33.1 SLC6A4 PRODH POMC OXT MAOA HTR2C
10 fibromyalgia 33.1 SLC6A4 POMC HTR2A HTR1A CRH COMT
11 eating disorder 33.0 SLC6A4 POMC HTR2C HTR2A CRH COMT
12 dysthymic disorder 33.0 WASF1 SLC6A4 SERPINA3 PRODH MAOA LIPA
13 sleep apnea 33.0 SLC6A4 HTR2C HTR2A BDNF
14 dementia 33.0 SERPINA3 HTR2A HTR1A COMT BDNF
15 mood disorder 32.9 SLC6A4 PRODH POMC MAOA HTR2C HTR2A
16 restless legs syndrome 32.9 SLC6A4 POMC MAOA COMT
17 alcohol use disorder 32.9 WASF1 SLC6A4 HTR2C HTR2A HTR1A H2AC18
18 asperger syndrome 32.9 SLC6A4 OXT COMT BDNF
19 gilles de la tourette syndrome 32.8 SLC6A4 MAOA HTR2A HTR1A COMT BDNF
20 bipolar i disorder 32.8 SLC6A4 HTR2C HTR2A HTR1A COMT BDNF
21 body dysmorphic disorder 32.8 SLC6A4 OXT MAOA HTR2A
22 schizotypal personality disorder 32.8 WASF1 PRODH COMT
23 parkinson disease, late-onset 32.8 SLC6A4 SERPINA3 PRODH MAOA HTR2A HTR1A
24 borderline personality disorder 32.7 SLC6A4 MAOA HTR2C HTR2A HTR1A CRH
25 migraine with or without aura 1 32.6 SLC6A4 POMC OXT MAOA HTR2C HTR2A
26 schizophrenia 32.6 SLC6A4 SERPINA3 PRODH POMC OXT MAOA
27 obsessive-compulsive disorder 32.5 SLC6A4 POMC OXT MAOA HTR2C HTR2A
28 autism spectrum disorder 32.5 SLC6A4 PRODH POMC OXT MAOA HTR2C
29 bulimia nervosa 32.5 SLC6A4 POMC OXT MAOA HTR2C HTR2A
30 endogenous depression 32.4 WASF1 SLC6A4 POMC OXT MAOA LIPA
31 conversion disorder 32.3 HTR2A COMT
32 avoidant personality disorder 32.2 WASF1 SLC6A4 MAOA
33 prion disease 32.2 SERPINA3 MIRLET7D MIR144 H2AC18
34 personality disorder 32.1 SLC6A4 MAOA HTR2C HTR2A HTR1A CRH
35 dementia, lewy body 32.1 SERPINA3 COMT BDNF
36 acute stress disorder 32.1 SLC6A4 POMC OXT CRH BDNF
37 generalized anxiety disorder 32.0 SLC6A4 PRODH MAOA HTR2C HTR2A HTR1A
38 alexithymia 31.9 SLC6A4 OXT HTR1A COMT
39 adjustment disorder 31.9 SLC6A4 HTR2A HTR1A BDNF
40 panic disorder 31.9 SLC6A4 POMC MAOA HTR2C HTR2A HTR1A
41 arteries, anomalies of 31.9 SERPINA3 MIRLET7D MIR144 H2AC18
42 post-traumatic stress disorder 31.8 SLC6A4 POMC MAOA HTR2A HTR1A CRH
43 alcohol dependence 31.8 SLC6A4 POMC OXT MAOA HTR2C HTR2A
44 conduct disorder 31.8 SLC6A4 POMC MAOA COMT
45 pulmonary disease, chronic obstructive 31.7 SLC6A4 SERPINA3 MIR144 H2AC18
46 pain agnosia 31.7 POMC OXT HTR1A
47 alzheimer disease 31.7 SLC6A4 SERPINA3 MAOA HTR2A HTR1A CRH
48 somatization disorder 31.7 SLC6A4 OXT HTR2A CRH
49 social phobia 31.6 WASF1 SLC6A4 SERPINA3 PRODH OXT MAOA
50 substance abuse 31.6 WASF1 SLC6A4 SERPINA3 PRODH POMC MAOA

Graphical network of the top 20 diseases related to Mental Depression:



Diseases related to Mental Depression

Symptoms & Phenotypes for Mental Depression

UMLS symptoms related to Mental Depression:


dejection emotional, depressed reaction, depression aggravated, affective symptoms, behavioral symptoms, schizophrenic language, depressive symptoms, depressed - symptom

MGI Mouse Phenotypes related to Mental Depression:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.2 BDNF COMT CRH DCTN1 HTR1A HTR2A
2 homeostasis/metabolism MP:0005376 10 BDNF COMT CRH DCTN1 DPP4 HTR1A
3 endocrine/exocrine gland MP:0005379 9.91 BDNF COMT CRH DPP4 HTR2A LIPA
4 integument MP:0010771 9.61 BDNF CRH HTR2C LIPA OXT POMC
5 nervous system MP:0003631 9.44 BDNF COMT CRH DCTN1 HTR1A HTR2C

Drugs & Therapeutics for Mental Depression

Drugs for Mental Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 908)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
2
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
3
Oxcarbazepine Approved Phase 4 28721-07-5 34312
4
Eleuthero Approved, Experimental Phase 4
5
Norethindrone Approved Phase 4 68-22-4 6230
6
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
7
Methimazole Approved Phase 4 60-56-0 1349907
8
Trimebutine Approved Phase 4 39133-31-8
9
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
10
Lactulose Approved Phase 4 4618-18-2 11333
11
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
12
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
13
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
14
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
15
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
16
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
17
Desipramine Approved, Investigational Phase 4 50-47-5 2995
18
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
19
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
20
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
21
Memantine Approved, Investigational Phase 4 19982-08-2 4054
22
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
23
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
24
leucovorin Approved Phase 4 58-05-9 6006 143
25
Zinc Approved, Investigational Phase 4 7440-66-6 32051
26
Iloperidone Approved Phase 4 133454-47-4 71360
27
Calcium carbonate Approved, Investigational Phase 4 471-34-1
28
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
29
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
30
Ribavirin Approved Phase 4 36791-04-5 37542
31
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
32
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
33
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
34
Ondansetron Approved Phase 4 99614-02-5 4595
35
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
36
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
37
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
38
Protriptyline Approved Phase 4 438-60-8 4976
39
Trimipramine Approved Phase 4 739-71-9 5584 4055
40
Isocarboxazid Approved Phase 4 59-63-2 3759
41
Maprotiline Approved, Investigational Phase 4 10262-69-8 4011
42
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
43
Zolpidem Approved Phase 4 82626-48-0 5732
44
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
45
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
46
Clonidine Approved Phase 4 4205-90-7 2803
47
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
48
Liraglutide Approved Phase 4 204656-20-2 44147092
49
Hydroxychloroquine Approved Phase 4 118-42-3 3652
50
Ranibizumab Approved Phase 4 347396-82-1 459903

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
2 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
3 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
4 Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
5 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder Unknown status NCT02051413 Phase 4 Venlafaxine extended release
6 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
7 Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression Unknown status NCT00291239 Phase 4
8 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
9 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
10 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
11 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
12 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
13 A Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Before and After Treatment With Desvenlafaxine Unknown status NCT02859103 Phase 4 Desvenlafaxine
14 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
15 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
16 Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life Unknown status NCT00889369 Phase 4 Duloxetine
17 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
18 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
19 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
20 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
21 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
22 White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study Unknown status NCT01492621 Phase 4 Desvenlafaxine
23 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
24 Behandlung Von Leichten Und Unterschwelligen Depressionen. Eine Randomisierte, Kontrollierte Studie Zum Wirksamkeitsnachweis Eines Serotonin-Wiederaufnahme-Hemmers (SSRI), Einer Kognitiven Verhaltenstherapie Und Einer Freien Therapiewahl ("Treatment of Mild and Subthreshold Depressive Disorders". A Randomized, Controlled Trial on the Efficacy of a Serotonin-Reuptake-Inhibitor (SSRI), a Cognitive-Behavioral Therapy and of Free Choice Between SSRI and CBT") Unknown status NCT00226642 Phase 4 Sertralin;Placebo
25 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
26 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
27 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
28 Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
29 A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
30 Clinical Psychopharmacology Division Institute of Mental Health, Peking University Unknown status NCT03148509 Phase 4 risperidone;aripiprazole;bupropion
31 THE AIUNI - Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
32 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
33 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
34 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
35 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
36 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy - a Monocentric, Double-Blind, Placebo-Controlled Trial Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
37 a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency) Unknown status NCT03290313 Phase 4 shu gan yi yang capsule;shu gan yi yang capsule simulation agent
38 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
39 Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial Unknown status NCT02777905 Phase 4
40 Treatment Prediction in Adolescent and Adult Depression Unknown status NCT00106197 Phase 4 Bupropion
41 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
42 TMSFOS: Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
43 An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression Unknown status NCT03567681 Phase 4 Extended release oxcarbazepine vs Immediate release oxcarbazepine
44 Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression Unknown status NCT01390662 Phase 4
45 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
46 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4 Drug treatment with Cymbalta
47 Collaborative Care for Depressed Elders in China Unknown status NCT01287494 Phase 4 Sertraline
48 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
49 Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy Unknown status NCT02579642 Phase 4 Ketamine;Placebo
50 A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate

Search NIH Clinical Center for Mental Depression

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam
Amitriptyline
Amitriptyline Hydrochloride
Amoxapine
Bupropion
Bupropion hydrobromide
Bupropion Hydrochloride
Buspirone
buspirone hydrochloride
Citalopram
Citalopram hydrobromide
Clomipramine
Clomipramine Hydrochloride
Desipramine
Desipramine Hydrochloride
Doxepin
Doxepin Hydrochloride
Escitalopram
Escitalopram oxalate
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Isocarboxazid
Isoflurane
Kava preparation
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Lorazepam
Maprotiline
Maprotiline Hydrochloride
Methylphenidate
Methylphenidate Hydrochloride
Mirtazapine
nefazodone
Nortriptyline
Nortriptyline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Phenelzine
Phenelzine Sulfate
Pramipexole
Pramipexole dihydrochloride
Protriptyline
Protriptyline Hydrochloride
Selegiline
selegiline hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam
Tranylcypromine
Tranylcypromine sulfate
Trazodone
Trazodone Hydrochloride
Tricyclic Antidepressant [EPC]
Trimipramine
Trimipramine Maleate
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: depression

Genetic Tests for Mental Depression

Genetic tests related to Mental Depression:

# Genetic test Affiliating Genes
1 Mental Depression 29

Anatomical Context for Mental Depression

MalaCards organs/tissues related to Mental Depression:

40
Brain, Testes, Heart, Breast, Cortex, Prefrontal Cortex, Lung

Publications for Mental Depression

Articles related to Mental Depression:

(show top 50) (show all 27847)
# Title Authors PMID Year
1
Triple reuptake inhibition of serotonin, norepinephrine, and dopamine increases the tonic activation of α2-adrenoceptors in the rat hippocampus and dopamine levels in the nucleus accumbens. 61
32474007 2020
2
Self-evaluation of negative symptoms in adolescent and young adult first psychiatric episodes. 61
32474008 2020
3
Brain stimulation rewarding experience attenuates neonatal clomipramine-induced adulthood anxiety by reversal of pathological changes in the amygdala. 61
32512130 2020
4
Significance of gastrointestinal tract in the therapeutic mechanisms of exercise in depression: Synchronism between brain and intestine through GBA. 61
32445660 2020
5
The structure and function of TRIP8b, an auxiliary subunit of hyperpolarization-activated cyclic-nucleotide gated channels. 61
32189562 2020
6
Common variants in FAN1, located in 15q13.3, confer risk for schizophrenia and bipolar disorder in Han Chinese. 61
32450113 2020
7
Establishing the dose of memory support to improve patient memory for treatment and treatment outcome. 61
31733608 2020
8
The selenocompound 1-methyl-3-(phenylselanyl)-1H-indole attenuates depression-like behavior, oxidative stress, and neuroinflammation in streptozotocin-treated mice. 61
32470357 2020
9
Brain structural and functional alterations in MDD patient with gastrointestinal symptoms: A resting-state MRI study. 61
32421626 2020
10
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? 61
32473843 2020
11
A novel pyrazole-containing selenium compound modulates the oxidative and nitrergic pathways to reverse the depression-pain syndrome in mice. 61
32417177 2020
12
Neuro-transcriptomic signatures for mood disorder morbidity and suicide mortality. 61
32485434 2020
13
Connectome-based models can predict early symptom improvement in major depressive disorder. 61
32560939 2020
14
Response to a recently published systematic review on intranasal esketamine for major depressive disorder. 61
32421597 2020
15
Pharmacogenetic association of bi- and triallelic polymorphisms of SLC6A4 with antidepressant response in major depressive disorder. 61
32421611 2020
16
Abnormal functional connectivity as neural biological substrate of trait and state characteristics in major depressive disorder. 61
32335266 2020
17
PSYCHOMETRIC properties of the Chinese version of the THINC-it tool for cognitive symptoms in patients with major depressive disorder. 61
32560957 2020
18
Psychiatric comorbidity in compulsive sexual behavior disorder (CSBD). 61
32244085 2020
19
Preliminary Study of the Impact of Single-Nucleotide Polymorphisms of IL-1α, IL-1β and TNF-α Genes on the Occurrence, Severity and Treatment Effectiveness of the Major Depressive Disorder. 61
31912349 2020
20
Difference in binocular rivalry rate between major depressive disorder and generalized anxiety disorder. 61
32461128 2020
21
Women with Major Depressive Disorder, Irrespective of Comorbid Anxiety Disorders, Show Blunted Bilateral Frontal Responses during Win and Loss Anticipation. 61
32421596 2020
22
Effects of transcranial direct current stimulation using miniaturized devices vs sertraline for depression in Korea: A 6 week, multicenter, randomized, double blind, active-controlled study. 61
32464489 2020
23
Feasibility of decision rule-based treatment of comorbid youth: A pilot randomized control trial. 61
32353635 2020
24
Efficacy of intensive short-term dynamic psychotherapy in mood disorders: A critical review. 61
32560931 2020
25
Inverse changes in telomere length between the blood and brain in depressive-like mice. 61
32560940 2020
26
Rate of diagnostic conversion to bipolar disorder in adults with unipolar depression and psychopharmacological treatment in the republic of Korea: A nationwide register-based study. 61
32421610 2020
27
A temporal relationship between nonmedical opioid Use and major depression in the U.S.: A Prospective study from the National Epidemiological Survey on Alcohol and Related Conditions. 61
32421616 2020
28
Affective Processing Biases in Relation to Past, Current, and Future Depression in Children and Adolescents. 61
32421595 2020
29
A missing link between depression models: Forced swimming test, helplessness and passive coping in genetically heterogeneous NIH-HS rats. 61
32454181 2020
30
Impaired neuronal and astroglial metabolic activity in chronic unpredictable mild stress model of depression: Reversal of behavioral and metabolic deficit with lanicemine. 61
32360130 2020
31
Enhanced conditioning of adverse memories in the mouse modified swim test is associated with neuroinflammatory changes - Effects that are susceptible to antidepressants. 61
32325189 2020
32
Antidepressant-like effect of hydroalcoholic extract from barks of Rapanea ferruginea: Role of monoaminergic system and effect of its isolated compounds myrsinoic acid A and B. 61
32361037 2020
33
The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences. 61
32145362 2020
34
Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. 61
31462766 2020
35
Peripheral immune aberrations in fibromyalgia: A systematic review, meta-analysis and meta-regression. 61
31887417 2020
36
Metacognitive beliefs in depressed in-patients: adaptation and validation of the short version of the Metacognitions Questionnaire (MCQ-30) for French clinical and non-clinical samples. 61
32522308 2020
37
Childhood maltreatment and the clinical characteristics of major depressive disorder in adolescence and adulthood. 61
32237880 2020
38
Major depressive disorder and cardiometabolic diseases: a bidirectional Mendelian randomisation study. 61
32270255 2020
39
Brain functional effects of electroconvulsive therapy during emotional processing in major depressive disorder. 61
32388195 2020
40
Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. 61
30374191 2020
41
Intrinsic connectomes are a predictive biomarker of remission in major depressive disorder. 61
31695168 2020
42
Suicidal attempts, insomnia, and major depressive disorder among family members of suicide victims in South Korea. 61
32553386 2020
43
Ensemble Learning for Early-Response Prediction of Antidepressant Treatment in Major Depressive Disorder. 61
31859419 2020
44
Editorial for "Ensemble Learning for Early-Response Prediction of Antidepressant Treatment in Major Depressive Disorder". 61
32034809 2020
45
Association between cognition and suicidal ideation in patients with major depressive disorder: A longitudinal study. 61
32379606 2020
46
Discovery and replication of cerebral blood flow differences in major depressive disorder. 61
31388104 2020
47
Serum FAM19A5 levels: A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder. 61
32217080 2020
48
Characterization of the signature of peripheral innate immunity in women with later-life major depressive disorder. 61
32217081 2020
49
The Association Between Adverse Childhood Experiences and Inflammation in Patients with Major Depressive Disorder: A Systematic Review. 61
32379599 2020
50
Association between major depressive disorder and multiple disease outcomes: a phenome-wide Mendelian randomisation study in the UK Biobank. 61
31427754 2020

Variations for Mental Depression

Expression for Mental Depression

Search GEO for disease gene expression data for Mental Depression.

Pathways for Mental Depression

GO Terms for Mental Depression

Cellular components related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 SERPINA3 POMC OXT MIRLET7D MIR185 MIR144
2 dendrite GO:0030425 9.35 HTR2C HTR2A HTR1A COMT BDNF
3 synapse GO:0045202 9.1 WASF1 SLC6A4 HTR2C HTR2A HTR1A CRH

Biological processes related to Mental Depression according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.88 HTR2C HTR2A HTR1A CRH
2 female pregnancy GO:0007565 9.77 OXT CRH COMT
3 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.69 HTR2C HTR2A HTR1A
4 response to drug GO:0042493 9.63 SLC6A4 HTR2C HTR2A CRH COMT BDNF
5 memory GO:0007613 9.62 SLC6A4 OXT HTR2A BDNF
6 locomotory exploration behavior GO:0035641 9.58 DPP4 CRH
7 sleep GO:0030431 9.57 OXT HTR2A
8 catecholamine metabolic process GO:0006584 9.56 MAOA COMT
9 dendrite extension GO:0097484 9.55 WASF1 BDNF
10 neurotransmitter catabolic process GO:0042135 9.54 MAOA COMT
11 dopamine catabolic process GO:0042420 9.52 MAOA COMT
12 regulation of appetite GO:0032098 9.49 POMC HTR2C
13 sperm ejaculation GO:0042713 9.48 SLC6A4 OXT
14 response to ether GO:0045472 9.46 OXT CRH
15 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.43 HTR2C HTR2A
16 behavior GO:0007610 9.43 HTR2C HTR2A HTR1A
17 regulation of serotonin secretion GO:0014062 9.4 HTR1A CRH
18 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.37 HTR2C HTR2A
19 serotonin receptor signaling pathway GO:0007210 9.13 HTR2C HTR2A HTR1A
20 behavioral fear response GO:0001662 8.92 HTR2C HTR1A DPP4 BDNF

Molecular functions related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.43 HTR2C HTR2A HTR1A
2 G protein-coupled serotonin receptor activity GO:0004993 9.33 HTR2C HTR2A HTR1A
3 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 8.96 HTR2C HTR2A
4 serotonin binding GO:0051378 8.92 SLC6A4 HTR2C HTR2A HTR1A

Sources for Mental Depression

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....